Technical Notes for NIS-Teen Vaccination Coverage Tables
The NIS-Teen has a sample size of over 22,000 adolescents with adequate vaccination coverage data reported by provider (adequate provider data). A sample is not the entire population. Sample estimates and population values may be different. The difference is measured through the 95% Confidence Interval (CI). For example, in 2015, the vaccination coverage estimate for 3 or more doses of human papillomavirus vaccine among adolescent girls in the United States was 62.9% +/-1.8%. This means that the true coverage was probably between 61.1% and 64.7%. When comparing two estimates (e.g., between states or between years), an overlap in the confidence intervals indicates that the observed difference might be due to chance.
Vaccination coverage estimates are presented as a point estimate (%) with a 95% CI. CIs around the coverage estimates are measures of precision; wide confidence intervals are a sign of a relatively small sample size and relatively less precision. Where confidence intervals overlap, the observed difference might be due to chance.
If an estimate is reported as NA (Not Available), the estimate was not reported because it may not be reliable or precise. If the unweighted sample size for the numerator was less than 30 or [(CI half-width)/Estimate] was greater than 0.6 the estimate may not be reliable or precise. The estimate for that subgroup is not reported. The individuals are still included in the overall sample and the overall estimate. State estimates with a CI half-width greater than 10 may be unreliable, but are reported and marked by a footnote.
Vaccination coverage estimates are based on provider-reported vaccination histories. Complex statistical methods are used to adjust for adolescents whose parents did not participate in the survey, lived in households without telephones, or immunization histories were not reported by their providers.
The adolescent’s race was reported by the parent or guardian. Hispanic adolescents can be of any race. Native Hawaiian or other Pacific Islanders and persons of multiple races were not included because of small sample sizes and the estimates may not be reliable or precise.Top of Page
|Adolescents in the survey period...||were born between|
|January 2014 - February 2015||January 1996 - February 2002|
|January 2013 – February 2014||January 1995 - February 2001|
|January 2012 – February 2013||January 1994 - February 2000|
|January 2011 – February 2012||January 1993 - February 1999|
|January 2010 - February 2011||January 1992 - February 1998|
|January 2009 - February 2010||January 1991 - February 1997|
|January 2008 - February 2009||January 1990 - February 1996|
|October 2007 - February 2008||October 1989 - February 1995|
|October 2006 - February 2007||October 1988 - February 1994|
The NIS-Teen estimates vaccination coverage for the 50 states and selected local areas.Top of Page
HepB: hepatitis B vaccine
≥3 HepB: 3 or more doses of HepB
HPV: human papillomavirus
≥1 HPV doses: 1 or more doses of HPV vaccine. HPV vaccination coverage estimates are reported separately for females and males.
≥2 HPV doses: 2 or more doses of HPV vaccine. HPV vaccination coverage estimates are reported separately for females and males.
≥3 HPV doses: 3 or more doses of HPV vaccine. HPV vaccination coverage estimates are reported separately for females and males.
HPV 3 dose series completion: the percent of females or males who received three or more doses of HPV vaccine among those who had at least one HPV vaccine dose and at least 24 weeks between the first dose and the NIS-Teen interview date.
MenACWY: quadrivalent meningococcal conjugate vaccine
≥1 MenACWY: 1 or more doses of MenACWY vaccine or meningococcal-unknown type vaccine.
MMR: measles-mumps-rubella vaccine
≥2 MMR: 2 or more doses of MMR
Td: tetanus-diptheria toxoids vaccine
Tdap: tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
≥1 Td or Tdap: 1 or more doses of Td or Tdap vaccine at or after the age of ten years.
≥1 Tdap: 1 or more doses of Tdap vaccine at or after the age of ten years.
VAR: varicella vaccine
≥1 VAR: 1 or more doses of VAR among those with no history of varicella disease by parental or provider report
≥2 VAR: 2 or more doses of VAR among those with no history of varicella disease by parental or provider report.Top of Page
- Page last reviewed: July 30, 2015
- Page last updated: September 9, 2016
- Content source: